Copanlisib Yields Responses in Relapsed/Refractory Non-Hodgkin Lymphoma
This video reviews results of the phase II CHRONOS-1 trial, a single-arm study evaluating the investigational agent copanlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma.
In this video, Martin Dreyling, MD, of the University of Munich in Germany, discusses results of the phase II CHRONOS-1 trial, an open-label, single-arm study evaluating the investigational PI3K inhibitor copanlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma.
Dreyling highlights the mechanism of action of copanlisib, reviews response rates in the overall study population and the subset of patients with marginal zone lymphoma, and discusses the toxicity profile and future directions of study with this agent.
The data were presented at the 2017 American Association for Cancer Research (AACR) Annual Meeting, held April 1–5 in Washington, DC.
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
![We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fd5a069c33bbfe917bc7c0b1bb13d76c0a815cc44-234x234.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.")
